Hematopoietic Malignancies Flashcards Preview

DD and BL (MHO) > Hematopoietic Malignancies > Flashcards

Flashcards in Hematopoietic Malignancies Deck (27)
Loading flashcards...

Mature Lymphoid Neoplasms (3)

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Plasma Cell Neoplasm


Nodular Lymphocyte Predominant Hodgkins Lymphoma (NLPHL)

B-cell orgin and indolent. Minority of large lymphocytes with multilobated nuclei ("popcorn" cells); majority are reactive to lymphocytes and histiocytes.


Classical Hodgkins Lymphoma (Pertinent cells and Markers)

Based on RS cells (large, many or multilobed nucleus, eosinophilic inclusion-like nucleolus, CD30+ and CD15+, large cytoplasm, and ned for common leukocyte CD45)


Classical Hodgkins Lymphoma (Manifestations (4))

1. Nodular Sclerosis: most common, effects young females, usually above the diaphragm, EBV in 10-25% , broad collagen bands and lacunar cells. 2) Mixed cellularity: 20-25% higher in kids and elderly, NO collagen bands, constituional B symptoms, EBV in 75%, below or both side of diaphragm. 3) Lymphocyte rich: 5% of CHL, RS cells present but rare. 4) Lymphocyte depleted: 1% of CHL (better prog.), no lymphocytes, numerous RS cells, some of which are anaplastic and bizzare (sarcomatous), and usually EBV+.


Types of Non-Hodgkin Lymphoma (4)

Burkitt lymphoma (GC B cell), follicular lymphoma (GC B cell), Mantle Cell Lymphoma (mantle cell), and SLL/CLL (pre or post GC, mature B cells)


Burkitt Lymphoma (GC B cell)

Aggressive; endemic (African, and jaw), sporadic (effects abdomen), starry sky pattern (tons of reactive cells surrounding macrophage), t(8;14) c-MYC (results in overexpression of cMYC, which results in a high proliferation index), CD10. CD19, CD20, BCL6, and MYC!, EBV in 30% sporadic cases.


Follicular Lymphoma (GC B cell)

40% of adult lymphoma, median age 60, indolent. Crowded follicles; node effacement, no mantle zone, polarity or starry sky. t(14;18) which causes overexpression of BCL2 and prevents apoptosis in cells that fail somatic mutation). CD10, CD19, CD20, BCL2!, and BCL6. Different from reactive follicularhyperplasia because variable follicle size, neg t(14;18) and neg BCL2.


Mantle Cell Lymphoma (mantle cell)

More in elderly and males; usu asymptomatic, effaced node, centroblst-like cells, characteristic t(11;14) (overexp. of BCL1, which increase CycD), CD19, CD20, CD5!, BCL1!, CD10, and BCL6 (neg for CD23)


SLL/CLL (pre or post GC, mature B cells)

CLL:blood lymphocytosis, BM involved, males and >65 years affected), most common leukemia of Western world. SLL: extramedullary site. Both: small round dense nuclei, with smudge cells, effaced nodes, 13q14 deletion in >50% of CLL. CD5, CD23!, CD19 (negative for CD10 or FMC7)


Plasma Cell Neoplasms Types (3)

Multiple/ Plasma Cell Myeloma, MGUS, and Plasmacytoma


Multiple/ Plasma Cell Myeloma

Usu >40 yrs, median age 68. CRAB symptoms (Hypercalcemia, renal insufficiency, anemia, and bone lesions), M spike meaning increase in immunoglobin, disturbs ionization of RBCs causes Rouleux formation on smear. Almost always need BM biopsy to diagnose; hypercellular with clockface chromatin and IgG inclusions. Lack antigenic diversity so more prone to infections.


Monoclonal Gammapathy of Undetermined Significance (MGUS)

M spike is present in protein electrophoresis, but no symptoms of Plasma Cell Myeloma. Have marrow plasmocytosis, no CRAB.


Plasmacytoma (Two types)

Solitary plasmacytoma of bone: local tumor of bone with multiple myeloma like cells (Diag: lesion in BONE, with PCM cells, no other lesions, no CRA, low/ no Mspike). Extraosseous plasmacytoma of bone: PCM-cell mass lesions outside of bone/ BM, usually in respiratory tract (75%); rare, median age 50 y w/ 2/3 favoring male.


Categories of AML

Congenital (cytogenetic findings), therapy related AML (t-AML), and AML,NOS


Congenital AML

RUNX1-RUNX1T1 t(8;21): RUNX! Encodes alpha subunit of CBF, good prognosis. CBFB-MYH11 inv(16) or t(16;16): see baso eos (immature eosinophils with baso granules), aka myelomonocytic leukemia, good prognosis, CBFB encodes beta subunit of CBF. PML-RARA t(15;17) aka PML: promyelocytes with faggot cells, RARA encodes for retinoic acid receptor alpha, can treat w/ ATRA and need to identify early because risk for DIC. MLL: bad prognosis. RBM15-MKL1 t(1;22): megaloblastic differentiation, often in infants with down syndrome; relatively good prognosis.



Alkylating agent or radiation: 2-8 year latency period; whole or partial loss of Chr. 5 and 7. Topoisomerase II Inhibitors: 1-2 year latency period, often has rearrangement of MLL gene; poor prognosis.



Molecular abnormalities: FLT3-ITD: poor prognosis, and trumps all. NPM1: good prognosis. CEBPA: good prognosis.



80-85% of ALL cases, CD19, CD22, and CD79a, lack CD20 of mature B cells. Three types: BCR-ABL t(9;22) (p190): more common in adults, worst prognosis of all AML (good prog in CML b/c of Gleevac). ETV6-RUNX1 t(12,21): 25% of childhood B-ALL, very favorable prognosis. MLL 11q23: common in neonates/ infants. Poor prognosis.



20-25% of ALL cases, CD2, CD3, CD7, CD99, and CD1a are markers. More in teenager males. May present with T-LBL w/ mediatinal mass), has better prognosis in children than adults.


Myelodysplastic Syndrome (MDS)- Characteristics and Types

Ineffective hematopoeisis and increased risk of progression to AML. Diagnosis: at least one peristent cytopenia, marrow findings with ring sideroblasts,, bilobed PMN, hypolobated small megakaryocytes. Two types: Primary/ Idiopathic (>50 y, insidious onset, w/ monosomy or delq Chr 5 and 7, trisomy 8) and Secondary/ Therapy-related (chemo drugs, B12/folic acid deficiency, virus, toxin, heavy metals, also related to t-AML with Chr 5 and 7 partial or whole deletion).


Low Grade MDS

Myeloblasts are less than 5% in BM. 1) RC-UD (good prog. Can specify further lineage, i.e. Refratory Neutropenia). 2) RC-MD (dysplasia in 2+ lineages w/ worst prognosis). 3) MDS with deletion 5q (associated with anemia, increased platelets, and marrow with distinctive megakaryocytes with small, round non-lobated nuclei).


High Grade MDS

Myeloblasts >5% of marrow cells. 1) Refractory Anemia with Excess Blasts (RAEB-1): 5-9% of blasts in marrow, median survival of 16 mo, with 25% progressing to AML. 2) Refractory Anemia Excess Blasts 2 (RAEB-2): 10-19% of blasts in marrow, median survival of 9 months, 33% transform to AML.


Myeloproliferative Neoplasms (Characteristics and Types)

Increase in one or more cell types (NO dysplasia), causes hypercellular marrow. Splenomegaly and/or hepatomegaly (sequestration and extramed. Hematopoiesis), can escalate to excessive marrow fibrosis leading to BM failure; can transform to acute leukemia or MDS). Types: CML, PV, PMF, and ET.


Chronic Myelogenous Leukemia (CML, a type of MPN)

Initial Phase: chronic; neutrophilia, BM hypercellularity, small megakaryocytes, no dysplasia. Blast Phase: transform to acute leukemia (AML or ALL) (>20% blast in marrow). BCR-ABL t(9;22) phil chr (p210) Tx w/ Imatinib, and dasatinib (2nd gen) PTKIs.


Polycythemia Vera (PV, a type of MPN)

Erythrocytosis; trilineage hyperplasia in marrow with clusters of large megakaryocytes. Nearly all have JAK2 mutations; most have V617F point mutation. Polycythemic Stage (increase in cell counts) and spent phase (marrow fibrosis and cell count decreases). Predilection for thromboisi (esp. mesenteric, portal, or splenic vein), treat with phlebotomy to reduce clotting.


Primary Myelofibrosis (PMF, a type of MPN)

Proliferation of granulocytic/ megakaryocytic lineages, marrow fibrosis. JAK2 mutations. Pre-fibrotic stage: BM hypercellularity w/ large mega to Fibrotic Stage: reticulin fibrosis of marrow, hypercellularity, dadrocytes, and extramed. hematopoiesis in spleen). Usu not diagnosed until fibrotic stage,median survival ~5 years; AML transformation not likely.


Essential Thrombocytopenia (ET, a type of MPN)

Usu asymptomatic, diagnosed from high platelet count; can have TIAs, digital ischemia w/ paraesthesia,thrombosis, NO splenomeg. Thrombocytosis, no granulocytic hyperplasia (normocellular marrow), large/bizarre mega, JAK2 mutations in 50% of patients, indolent disease, rarely progress.